Related Experiment Videos
Conjugate pneumococcal vaccines: an overview
1Department of Paediatrics, University of Melbourne, VIC. mulhollk@cryptic.rch.unimelb.edu.au
Insights
A seven-valent pneumococcal conjugate vaccine effectively prevents invasive pneumococcal disease in infants. Ongoing research explores global vaccine development and potential serotype replacement, while also noting reduced antimicrobial resistance.
Area of Science:
- * Vaccinology and Infectious Diseases
- * Public Health and Epidemiology
Background:
- * The seven-valent pneumococcal conjugate vaccine (PCV7) demonstrated significant efficacy against invasive pneumococcal disease (IPD).
- * PCV7 showed lesser efficacy against otitis media and pneumonia, highlighting the need for broader serotype coverage.
- * Licensed in the US in 2000, PCV7 is recommended for routine infant immunization and catch-up vaccination in high-risk children.
Purpose of the Study:
- * To review the efficacy and impact of the seven-valent conjugate pneumococcal vaccine.
- * To discuss the development of broader-valent vaccines for global use.
- * To address challenges and considerations for vaccine introduction in developing countries.
Main Methods:
- * Review of clinical trial data and epidemiological studies on pneumococcal conjugate vaccines.
- * Analysis of vaccine effectiveness, serotype distribution, and antimicrobial resistance patterns.
- * Consideration of global vaccine development and implementation strategies.
Main Results:
- * Dramatic efficacy of PCV7 against invasive pneumococcal disease was confirmed.
- * Evidence of serotype replacement in vaccine recipients was observed, potentially impacting long-term effectiveness.
- * Vaccine introduction may lead to reduced rates of antimicrobial resistance in pneumococci.
Conclusions:
- * The seven-valent pneumococcal conjugate vaccine is highly effective against IPD.
- * Development of 9- and 11-valent vaccines is underway for broader global impact.
- * Addressing the cost and implementation challenges is crucial for developing countries to benefit from these vaccines.
Abstract:
A seven-valent conjugate pneumococcal vaccine has been shown to have dramatic efficacy against invasive pneumococcal disease and lesser efficacy against otitis media and pneumonia. This vaccine was licensed for use in infants in the United States in February 2000 and is recommended there for routine use in infants and catch-up vaccination in high-risk children. Specific regional pneumococcal vaccines are not needed; nine to 11 serotypes cover most pneumococcal disease in most parts of the world; nine- and 11-valent conjugate vaccines are currently being developed for the global market. There is evidence of serotype replacement in vaccine recipients (in both carriage and disease), which might reduce overall vaccine effectiveness. There is also evidence that vaccines may reduce rates of antimicrobial resistance in pneumococci. Studies of the burden of pneumococcal disease as well as program support are needed to assist developing countries to introduce these expensive vaccines.